바이오 부문

Innovative BioConvergence Company for Healthier Life

Lead New Therapeutic Paradigm via Converging Bio and Information Technology

Establish Growth Engine Focused on Cancer and Digital Therapy
Diversify Portfolio to Reinforce its Value

Business Areas
of Interest.

Business Areas
of Interest.

2020 KEY EVENTS.

CANCER THERAPEUTICS_

In-Licensing 1^st Oncology Product, Nerlynx®
NDA Filing for Nerlynx® in Korea
Initiate/Assess Next In-Licensing Oncology Products

IDE* Filing for 1^st DTx Products in US
Initiate Clinical Trial for 1^st DTx Product in US
Strategy Investment to Digital Healthcare Space

DIGITAL THERAPEUTICS_

*IDE: Investigational Device Exemption